Phuturdex › Diseases › Idiopathic pulmonary fibrosis
Drugs in development · updated 30 October 2026
Idiopathic pulmonary fibrosis: drugs in development
As of 30 October 2026 there are 56 active clinical trials (recruiting or ongoing, phases I–III) on 57 drugs for idiopathic pulmonary fibrosis. 41 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BMS-986278 | III | 2 | NCT07441408 |
| Deupirfenidone | III | 2 | NCT07284602 |
| HEC585 | III | 2 | NCT07082842 |
| INS018_055 | III | 2 | NCT07687459 |
| AK3280 | III | 1 | NCT07719023 |
| SC1011 | II–III | 1 | NCT06125327 |
| TDI01 | III | 1 | NCT07464912 |
| SV001 | II | 2 | NCT07121413 |
| ABBV-142 | II | 1 | NCT07230288 |
| AGMB-447 | II | 1 | NCT07862634 |
| AnlotinibAL3818, Anrotinib | II | 1 | NCT05828953 |
| AP02 | II | 1 | NCT07194382 |
| AZD8965 | II | 1 | NCT07652658 |
| BC006 | II | 1 | NCT07447102 |
| BI 765423 | II | 1 | NCT07036523 |
| BuloxibutidCompound 21 | II | 1 | NCT06588686 |
| CD19 | I–II | 1 | NCT03500731 |
| CHF10067 | II | 1 | NCT07516951 |
| DWN12088 | II | 1 | NCT05389215 |
| ENV-101 | II | 1 | NCT06422884 |
| HSK44459 | II | 1 | NCT07019090 |
| HSK50042 | II | 1 | NCT07728721 |
| Hymecromone | II | 1 | NCT06325696 |
| LTI-03 | II | 1 | NCT06968845 |
| ME-015 | II | 1 | NCT05983471 |
| MTX-463 | II | 1 | NCT06967805 |
| Nicotinamide ribosideNicotinamide ribonucleoside | II | 1 | NCT06567717 |
| Oral Ifetroban | II | 1 | NCT05571059 |
| ORJ-001 | II | 1 | NCT07869147 |
| PIPE-791 | II | 1 | NCT07284459 |
| RE104 for Injection | II | 1 | NCT07002034 |
| Saracatinab | I–II | 1 | NCT04598919 |
| SB17170 | II | 1 | NCT06747923 |
| SC01009 | II | 1 | NCT07131150 |
| Senicapoc | II | 1 | NCT06714123 |
| SYH2059 | II | 1 | NCT07600021 |
| Artesuante | I | 1 | NCT05988463 |
| CHF10073 | I | 1 | NCT07876284 |
| SCB0020160 | I | 1 | NCT07682337 |
| SRN001 | I | 1 | NCT07407543 |
Sorted by most advanced phase and number of active trials. Showing 40 of 41 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PirfenidoneEsbriet®, Pirfenidone Viatris® | III | 6 | NCT07284602 |
| LansoprazoleLanzoprazole, Prevacid 24 Hr® | III | 1 | NCT04965298 |
| MetforminRiomet Er®, Glumetza® | III | 1 | NCT07520110 |
| NerandomilastBI 1015550, Jascayd® | III | 1 | NCT06238622 |
| TreprostinilTyvaso Dpi®, Yutrepia® | III | 1 | NCT04905693 |
| NintedanibNintedanib Accord®, Vargatef® | II | 3 | NCT07679893 |
| RituximabRuxience, Rituxan | I–II | 2 | NCT03500731 |
| AlemtuzumabCampath, Lemtrada® | I–II | 1 | NCT03500731 |
| AxatilimabNiktimvo® | II | 1 | NCT06132256 |
| DextromethorphanDextromethophan | II | 1 | NCT07583589 |
| FludarabineFludara, FLUDARABIN | I–II | 1 | NCT03500731 |
| HydroxyureaHydroxycarbamide, Hydroxycarbamid | I–II | 1 | NCT03500731 |
| IdelalisibCAL101, Zydelig® | II | 1 | NCT06736990 |
| ThiotepaTepylute®, Tepadina And Sodium Chloride® | I–II | 1 | NCT03500731 |
| ZincWilzin® | II | 1 | NCT06567717 |
Sorted by most advanced phase and number of active trials. Showing 15 of 16 drugs.
All 57 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Interstitial lung disease 65 drugs
- Idiopathic interstitial pneumonia 4 drugs
- Extrinsic allergic alveolitis 3 drugs
- Radiation Pneumonitis 5 drugs
- Pulmonary fibrosis 34 drugs
Broader categories
- Respiratory disease 57 drugs
- Lung disease 104 drugs
- Interstitial lung disease 65 drugs
- Pulmonary fibrosis 34 drugs
- Fibrosis 52 drugs
- Respiration disorder 6 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D054990 “Idiopathic Pulmonary Fibrosis”. Prevalence: Orphanet.